Il faut faire preuve d'une vigilance particulière si le patient prend des médicaments à fort
potentiel d'interactions médicamenteuses: antiarythmiques (amiodarone, digoxine) …

Objectives Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral
agent targeting the 3-chymotrypsin–like cysteine protease enzyme (3C-like protease or …

Background Five-day oral therapies against early COVID-19 infection have recently been
conditionally approved in Europe. In the drug combination nirmatrelvir+ ritonavir …

Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with
coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe …

In this perspective, we highlight major clinical pharmacologyrelated issues encountered
since the rapid introduction of nirmatrelvir/ritonavir in Israel. We describe the rationale for the …

Abstract Background Coronavirus disease 2019 (COVID‐19) is a highly contagious,
airborne viral infection that can infect anyone. Those with certain underlying conditions may …

This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among
66 007 patients with coronavirus disease 2019 in a large health care system. A possible …

The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has
been granted authorization or approval in several countries for the treatment of patients with …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

Nirmatrelvir plus Ritonavir (Paxlovid) will be used in Spain soon. 1 A lthough the potential
effect of the drug against COVID-19 infection has biochemical explanation and has been …